Table 2.
Pulmonary function and laboratory data before and after NTB treatment
| Pulmonary function data / Laboratory data | Total (n = 26) |
NTB group (n = 15) | NTB + IS group (n = 11) |
p |
|---|---|---|---|---|
| At the start of NTB treatment | ||||
| VC (vital capacity) | ||||
| % of predicted value, % | 64.8 ± 17.0 | 65.8 ± 18.8 | 63.4 ± 14.9 | 0.876 |
| mean value, mL | 1,860.4 ± 709.2 | 1,965.3 ± 816.3 | 1,717.3 ± 534.5 | 0.378 |
| FVC (forced vital capacity) | ||||
| % of predicted value, % | 62.5 ± 16.7 | 64.3 ± 18.7 | 60.1 ± 14.0 | 0.586 |
| FEV1/FVC (forced expiratory volume in 1 s divided by forced vital capacity) | ||||
| mean value, % | 89.4 ± 6.8 | 86.6 ± 6.7 | 93.2 ± 5.1 | 0.020* |
| DLCO (diffusing capacity for carbon monoxide) † | ||||
| % of predicted value, % | 48.1 ± 24.3 (n = 15) | 56.4 ± 24.4 (n = 8) | 38.7 ± 22.1 (n = 7) | 0.272 |
| DLCO/VA (diffusing capacity for carbon monoxide divided by alveolar volume) † | ||||
| % of predicted value, % | 71.9 ± 27.0 (n = 15) | 76.6 ± 20.2 (n = 8) | 66.6 ± 34.2 (n = 7) | 0.524 |
| Monthly change in FVC before NTB treatment§, %/month | −0.70 ± 0.56 (n = 18) | −0.46 ± 0.35 (n = 11) | −1.07 ± 0.65 (n = 7) | 0.024* |
| KL-6, U/mL | 1,240.1 ± 839.7 | 1,001.7 ± 661.5 | 1,565.2 ± 974.1 | 0.040* |
| After NTB treatment | ||||
| Follow-up period since NTB was started, months | 8.4 ± 2.3 | 8.1 ± 2.4 | 8.8 ± 2.0 | 0.351 |
| VC (vital capacity) | ||||
| % of predicted value, % | 67.9 ± 18.5 | 64.0 ± 19.1 | 73.3 ± 17.1 | 0.276 |
| mean value, mL | 1,941.9 ± 760.4 | 1,908.0 ± 823.3 | 1,988.2 ± 701.7 | 0.917 |
| FVC (forced vital capacity) | ||||
| % of predicted value, % | 67.0 ± 17.2 | 63.2 ± 17.6 | 72.3 ± 15.8 | 0.213 |
| FEV1/FVC (forced expiratory volume in 1 s divided by forced vital capacity) | ||||
| mean value, % | 86.5 ± 9.5 | 84.5 ± 10.9 | 89.3 ± 6.6 | 0.213 |
| DLCO (diffusing capacity for carbon monoxide) † | ||||
| % of predicted value, % | 46.0 ± 24.0 (n = 15) | 50.6 ± 28.0 (n = 8) | 40.7 ± 19.3 (n = 7) | 0.643 |
| DLCO/VA (diffusing capacity for carbon monoxide divided by alveolar volume) † | ||||
| % of predicted value, % | 68.4 ± 24.4 (n = 15) | 69.3 ± 26.0 (n = 8) | 67.3 ± 24.5 (n = 7) | 0.772 |
| Monthly change in FVC after NTB treatment§, %/month | + 0.54 ± 1.56 (n = 18) | −0.17 ± 0.86 (n = 11) | + 1.50 ± 1.81 (n = 7) | 0.001** |
| KL-6, U/mL | 964.4 ± 597.2 | 883.3 ± 518.7 | 1,075.1 ± 974.1 | 0.468 |
Data are expressed as mean ± standard deviation (SD). NTB: nintedanib; IS: immunosuppressive agents; KL-6: Krebs von den Lungen-6
† DLCO was measured in 15 of 26 patients
§ The monthly change in FVC (%/month) before and after NTB treatment was calculated for 18 of the 25 patients who underwent a pulmonary function test before NTB treatment (within 24 months before the start of NTB), at the start of NTB treatment (within 3 months before the start of NTB), and after NTB treatment (6–12 months after the start of NTB).
For statistical analyses, *p < 0.05, **p < 0.01. P-value: Wilcoxon signed rank test, Fisher’s exact test